title: Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
abstract: BACKGROUND
  Numerous phase II and III clinical trials have demonstrated a higher activity of combined gemcitabine plus docetaxel schedules against non-small cell lung cancer (NSCLC) than that of both agents in monotherapy.
  
  
  METHODS
  This phase II study evaluated a 3-week based schedule of docetaxel 85 mg/m(2) (1-h i.v. infusion, d8) combined with gemcitabine 1,000 mg/m(2) (30-min i.v. infusion; d1,8) as first-line chemotherapy for patients with advanced NSCLC.
  
  
  RESULTS
  Forty-one patients with non-resectable, stage IIIB/IV, and bidimensionally measurable disease were enrolled. A total of 182 chemotherapy cycles (median 6, range 1-6) was administered to 40 patients during the study; one patient did not receive chemotherapy due to a protocol deviation. Two patients were not evaluable for treatment efficacy. The overall response rate found was 44% (95% CI, 29-59%): three patients (7%) had a complete response and 15 patients (37%) had a partial response (median duration of response = 4.0 months). With a median follow-up of 8.7 months, the median time to disease progression was 4.4 months and the median overall survival was 7.3 months. The combined gemcitabine plus docetaxel chemotherapy was well tolerated except for pulmonary toxicity. The main grade 3-4 hematological toxicity was neutropenia (28% of patients, 9% of cycles). Two cases of febrile neutropenia were reported. The main grade 3-4 non-hematological toxicity was pulmonary toxicity (23% of patients, 6% of cycles).
  
  
  CONCLUSIONS
  Gemcitabine 1,000 mg/m(2) on days 1 and 8 in combination with docetaxel 85 mg/m(2) on day 8 given in 3-week cycles is an active and well-tolerated first-line chemotherapeutic regimen for advanced NSCLC.
authors.affiliation: Medical Oncology Department, Hospital Do Meixoeiro, Pontevedra, Spain. joaquin.casal.rubio@sergas.es
authors.forename: Joaquín
authors.initials: J
authors.lastname: Casal
authors.forename: Margarita
authors.initials: M
authors.lastname: Amenedo
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Mel
authors.forename: Luis Miguel
authors.initials: LM
authors.lastname: Antón
authors.forename: Rubén
authors.initials: R
authors.lastname: Rodríguez-López
authors.forename: Rafael
authors.initials: R
authors.lastname: López-López
authors.forename: Ana
authors.initials: A
authors.lastname: González-Ageitos
authors.forename: Javier
authors.initials: J
authors.lastname: Castellanos
authors.forename: Manuel
authors.initials: M
authors.lastname: Constenla
authors.forename: José L
authors.initials: JL
authors.lastname: Tisaire
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage*; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine